Positive Preliminary Data of Vebreltinib in Patients with Non-CNS MET Fusion Solid Tumors from Ph 2 SPARTA Trial Announced
“We are very pleased with the preliminary data showing 43% objective response rate in patients with non-CNS MET fusion solid tumors. The results in this specific cohort of patients adds to the accumulating evidence supporting the potential of vebreltinib as a highly selective and efficacious treatment against multiple tumor types harboring MET alterations. Alongside the Avistone data for vebreltinib in the treatment of gliblastoma with PTPRZ1 MET fusions, the clinical evidence for the efficacy of vebreltinib in MET fusions is very encouraging,” said Guo-Liang Yu, Ph.D., Chairman and Chief Executive Officer of Apollomics. “Based on the overall occurrence of these fusions in 0.1-0.3% of solid tumors, we believe the incidence is several thousand per year in the United States. Given the increasing patient access to next-generation sequencing, we expect it will become increasingly practical to identify and treat these patients with a targeted therapy such as vebreltinb. We look forward to providing additional clinical updates from the SPARTA Phase 2 trial as they become available.”
Share:
More News
“The positive outcome of our pre-IND interactions with the FDA reinforces the development pathway for MaaT034 and supports its continued advancement toward the clinic. It also represents an important step in MaaT Pharma’s expansion into immuno-oncology, highlighting the broader potential of our first in class co-cultivated microbiome donor-independent platform across
“Patients with metastatic RAS G12D non-squamous NSCLC, occurring in approximately 4% of cases, represent an underserved population, with no approved targeted treatment options. Initial clinical data evaluating zoldonrasib in combination with standard of care pembrolizumab and platinum doublet chemotherapy in patients with previously untreated metastatic RAS G12D non-squamous NSCLC showed
“At Georgiamune, we are focused on uncovering novel mechanisms that control immune-cell function and translating that biology into first-in-class medicines across autoimmune disease and oncology,” said Samir N. Khleif, M.D., Founder and Chief Executive Officer of Georgiamune. “GIM-621 is one of multiple programs to emerge from that work, alongside three
“Our team’s outstanding execution has enabled us to rapidly advance three programs into the clinic in 2026 and make significant progress in developing next-generation IO, ADC and combination therapies. Together with our partner, Kelun-Biotech, we have achieved seven IND clearances to date, and by mid-2027, we expect more than 2,000